Amylin Pharmaceuticals built on gains from the previous three sessions and traded with a top volume of 2012 after getting an approval from U.S. Food and Drug Administration (FDA) for BYDUREON which is the first of its kind that allows only once-weekly treatment for type 2 diabetes and is expected to be available in February.

Top three biotechnology stocks with massive percentage gains were Bionovo Inc. (NASDAQ:BNVI) with a rally of 33.33% after taking decision of a voluntary delisting from the NASDAQ Capital Market because of the minimum $1.00 per share requirement, StemCells, Inc. (NASDAQ:STEM) soared 17.44% to mark the best since December 15 and ImmunoGen, Inc. (NASDAQ:IMGN) climbed 10.02% after showing better-than-expected financial results.

Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN) started last trading at an opening price of $12.29 and during the session hit at $12.41 but when closing bell rang the stock finally advanced 1.68% to $12.14.

The stock had a trade volume of 6.42 million shares was more as compared to average trading capacity of 2.05 million shares. The company’s week performance appeared as +6.21%, 1 year performance moved at -26.16%, and year-to-date performance emerged positive with +6.68% while a month-performance after last close went up at +5.75%.

Shares price of AMLN moved up from its 20 days moving average with +6.58% and remote positively from 50 days moving average with +11.69%. AMLN current year earnings per share experienced an addition with 19.83% while its current quarter performance remained +5.75%. Company’s beta coefficient included 1.54. Beta factors measures the amount of market risk associated with market trade.

AMLN is ahead its 52 week low with 51.18% and logging behind from its 52 week high price with -27.09%. AMLN stock price volatility for a week moved about 4.36%. In share capital AMLN has 146.28 million outstanding shares among them 145.73 million shares have been floated in market exchange. AMLN stock institutional ownership remained 84.86% while insider ownership included 0.26%.

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. galaxystocks.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer ( http://galaxystocks.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold galaxystocks.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.